Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of switching from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension

X
Trial Profile

Efficacy and safety of switching from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary) ; Sildenafil
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2017 New trial record
    • 08 Apr 2017 Primary endpoint of prevalence of patients in WHO functional class III/IV after drug switch has been met, according to results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 08 Apr 2017 Results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top